Last reviewed: July 7, 2026

Last updated: July 7, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Wegovy (semaglutide) is an FDA-approved injectable medication for weight loss that activates GLP-1 receptors in the brain to reduce appetite and food intake. Understanding the medical requirements to qualify for this therapy—and knowing your access options—can help you pursue safe, effective treatment without the insurance barriers many patients face.

BMI and Weight Loss Eligibility Criteria for Semaglutide

The primary medical requirement for Wegovy qualification is a body mass index (BMI) of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition such as type 2 diabetes, hypertension, or cardiovascular disease. Your healthcare provider calculates BMI using your height and current weight to determine if you meet the threshold for pharmacotherapy. Some patients with a BMI between 27 and 29.9 may still qualify if they have documented obesity-related complications, though this requires individual clinical assessment.

Age is another consideration: semaglutide therapy is approved for adults 18 and older, though additional caution applies to patients over 65 who may have greater medication sensitivity. Your provider must also review your personal and family history of thyroid cancer or medullary thyroid carcinoma (MTC), as semaglutide carries a black-box warning for this specific contraindication. PlexusDx medical providers evaluate each patient's health profile individually to confirm both safety and appropriateness before initiating treatment.

Medical Evaluation and Provider Assessment Requirements

Before receiving a semaglutide prescription, you must complete a comprehensive medical consultation with a licensed provider who can assess your overall health status, medication interactions, and weight loss history. This evaluation typically includes review of your current medications, kidney and liver function, blood sugar control, and any previous attempts at diet and exercise interventions. Providers ask about prior bariatric surgery, gastrointestinal disorders, and pancreatitis history because these conditions may affect semaglutide safety or efficacy.

PlexusDx providers conduct detailed initial assessments via telehealth to gather this medical information and determine whether semaglutide injection or oral formulations best suit your needs. Your provider may order baseline labs or review existing results to establish a safe starting point for therapy. This personalized evaluation ensures you receive the right medication and dosing strategy from day one, rather than a one-size-fits-all approach.

How PlexusDx Ensures Safe Access Without Insurance Barriers

PlexusDx eliminates common obstacles to GLP-1 therapy by offering compounded semaglutide injections from licensed 503A pharmacies at transparent, flat-rate pricing starting at $189 per month—with no insurance requirement, no membership fees, and no flat per-compound pricing increases. Your dose may need to go up. Your price won't. This pricing model removes the financial uncertainty that prevents many patients from accessing weight loss medications through traditional insurance channels, where prior authorizations and coverage denials delay or block treatment entirely.

All PlexusDx medications are compounded under strict quality standards at licensed 503A facilities, ensuring safety and potency throughout treatment. PlexusDx serves all 50 states, making semaglutide accessible regardless of geographic location or insurance status. Patients can also apply HSA and FSA funds to their treatment, further reducing out-of-pocket costs.

Genetic Testing for Personalized Semaglutide Response

The PlexusDx Precision Peptide Genetic Test analyzes GLP1R, GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to Wegovy or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

The Precision Peptide Genetic Test costs $99 as an add-on after your first month of treatment, giving you data-driven insight into whether semaglutide injection, oral semaglutide, tirzepatide, or dual-compound GLP-Squared therapy will deliver optimal results for your specific genetic profile. Patients with favorable GLP1R and GIPR variants often show faster response, while those with specific FTO variants may benefit from higher efficacy agents like tirzepatide.

Safety Considerations and Contraindications to Discuss

While semaglutide is well-tolerated in most patients who meet eligibility criteria, certain medical conditions require avoidance or careful monitoring. Absolute contraindications include personal or family history of medullary thyroid cancer, multiple endocrine neoplasia syndrome type 2 (MEN2), severe allergic reactions to semaglutide or its components, and current or recent pancreatitis. Relative contraindications—conditions requiring closer supervision—include diabetic retinopathy, kidney disease, gallbladder disease, and pregnancy or breastfeeding.

Your PlexusDx provider screens for these conditions during your initial assessment and may recommend alternative compounds or close monitoring if relative contraindications exist. Common side effects include nausea, constipation, and fatigue during dose escalation, but these typically resolve within 1-2 weeks as your body adjusts. Serious adverse events are rare when therapy is medically supervised, making PlexusDx's provider-led model essential for safe, confident treatment.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $189/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the minimum BMI required to qualify for Wegovy or semaglutide therapy?

The standard threshold is a BMI of 30 or higher, or 27 or higher if you have weight-related health conditions like diabetes or hypertension. PlexusDx providers evaluate your individual medical history to confirm eligibility and recommend the safest medication option for your situation.

Do I need insurance or a pre-authorization letter to access semaglutide through PlexusDx?

No. PlexusDx operates without insurance requirements, membership fees, or prior authorization delays. Semaglutide injections start at $189/mo (or $149/mo on the 6-month plan) with transparent, flat-rate pricing across all commitment tiers, and you can use HSA or FSA funds to offset costs.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GLP1R, GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Are PlexusDx compounded medications as safe as brand-name Wegovy?

Yes. PlexusDx sources all compounded semaglutide from licensed 503A pharmacies—the highest regulatory standard for compounding in the United States. These facilities follow strict manufacturing and quality-control protocols, though compounded medications are not FDA-approved in the way brand products are.

What medical conditions would disqualify me from semaglutide therapy?

Absolute contraindications include personal or family history of medullary thyroid cancer, MEN2 syndrome, and severe allergies to semaglutide. Conditions like diabetic retinopathy, kidney disease, and pancreatitis require close provider monitoring but do not automatically disqualify you. PlexusDx providers review your complete medical history during your initial telehealth consultation.

Related Reading

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves